News
Public · Published
HC Wainwright & Co. upgrades Inovio Pharmaceuticals to Buy from Neutral, sets price target at $5
HC Wainwright & Co. upgraded Inovio Pharmaceuticals from Neutral to Buy and set a $5 price target. The article says that target implies 730.0% upside from the October 30 closing price of $0.60.
Published:
Updated:
What happened
HC Wainwright & Co. upgraded Inovio Pharmaceuticals from Neutral to Buy and set a $5 price target. The article says that target implies 730.0% upside from the October 30 closing price of $0.60.
Confirmed
Global impact / market context
A Buy rating and a much higher stated target may draw investor attention to Inovio shares, potentially changing trading demand. The target is an analyst view, not a promised return, and does not itself change the company’s revenue, costs, or available cash.
Analyst inference
The supplied article reports one firm’s rating change and target, but gives no company results, clinical developments, or explanation for the target. The stated upside compares the target with an earlier closing price; it is not evidence that the share price will reach $5.
Analyst inference
What to watch
- Whether other analysts change their ratings or targets could show whether the positive view is shared, though the article reports only HC Wainwright & Co.’s action. Analyst inference
- Future company updates on results or development progress could provide evidence relevant to the $5 target; the supplied article does not identify supporting assumptions. Analyst inference
- The article gives October 30’s closing price as $0.60, but supplies no later price, so any subsequent share-price movement remains unknown here. Confirmed
Evidence
- Original source link unavailable